---
title: "EVEREST MED: Performance is expected to grow significantly by 142% in 2025, achieving a turnaround to profitability"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280560489.md"
description: "36Kr learned that the Hong Kong innovative pharmaceutical company EVEREST MED disclosed its full-year performance report for 2025. The data shows that the company achieved total revenue of 1.707 billion yuan in 2025, a significant increase of 142%; it turned a profit under Non-IFRS standards, earning 187 million yuan, and achieved positive operating cash flow in the fourth quarter. As of December 31, 2025, the company had ample cash reserves of 2.731 billion yuan, strongly supporting commercialization expansion, independent research and development, and medium to long-term strategic layout"
datetime: "2026-03-26T03:32:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280560489.md)
  - [en](https://longbridge.com/en/news/280560489.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280560489.md)
---

# EVEREST MED: Performance is expected to grow significantly by 142% in 2025, achieving a turnaround to profitability

36Kr learned that the Hong Kong innovative pharmaceutical company EVEREST MED disclosed its full-year performance report for 2025. The data shows that the company achieved total revenue of 1.707 billion yuan in 2025, a significant increase of 142%; it turned a profit under Non-IFRS standards, earning 187 million yuan, and achieved positive operating cash flow in the fourth quarter. As of December 31, 2025, the company had ample cash reserves of 2.731 billion yuan, strongly supporting commercialization expansion, independent research and development, and medium to long-term strategic layout

### Related Stocks

- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [159567.CN](https://longbridge.com/en/quote/159567.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [01952.HK](https://longbridge.com/en/quote/01952.HK.md)
- [159570.CN](https://longbridge.com/en/quote/159570.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)

## Related News & Research

- [Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation | ONNVF Stock News](https://longbridge.com/en/news/285274936.md)
- [Grand Pharmaceutical Moves to Adopt New Bye-Laws Aligned With HK Paperless Regime](https://longbridge.com/en/news/284576690.md)
- [11:14 ETRibo y Boehringer Ingelheim siguen avanzando en su programa de siRNA](https://longbridge.com/en/news/285402650.md)
- [ZAWYA: Emirates Drug Establishment approves first nasal epinephrine spray as alternative to injections for severe allergic reaction](https://longbridge.com/en/news/284603051.md)
- [GenFleet Asserts Independent IP for Pan RAS Inhibitor GFH276 Amid Sector Dispute](https://longbridge.com/en/news/284312081.md)